lorazepam has been researched along with Age-Related Memory Disorders in 14 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The benzodiazepine lorazepam is widely utilized in the treatment of elderly individuals with anxiety disorders and related conditions." | 3.81 | Adverse performance effects of acute lorazepam administration in elderly long-term users: pharmacokinetic and clinical predictors. ( Bruno, D; Greenblatt, DJ; Lee, SH; Petkova, E; Pomara, N; Sidtis, JJ; Silber, T, 2015) |
| " The results have implications for evaluating the safety of the long-term use of BZ medications." | 1.27 | Chronic use of benzodiazepines and psychomotor and cognitive test performance. ( Geller, AM; Lucki, I; Rickels, K, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (28.57) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pomara, N | 2 |
| Lee, SH | 1 |
| Bruno, D | 1 |
| Silber, T | 1 |
| Greenblatt, DJ | 2 |
| Petkova, E | 1 |
| Sidtis, JJ | 2 |
| Stonnington, CM | 1 |
| Snyder, PJ | 1 |
| Hentz, JG | 1 |
| Reiman, EM | 1 |
| Caselli, RJ | 1 |
| Willoughby, L | 1 |
| Wesnes, K | 1 |
| Wezenberg, E | 1 |
| Sabbe, BG | 1 |
| Hulstijn, W | 1 |
| Ruigt, GS | 1 |
| Verkes, RJ | 1 |
| Schlösser, RG | 1 |
| Gesierich, T | 1 |
| Wagner, G | 1 |
| Bolz, M | 1 |
| Gründer, G | 1 |
| Dielentheis, TF | 1 |
| Scherb, C | 1 |
| Stoeter, P | 1 |
| Gilles, C | 1 |
| Luthringer, R | 1 |
| Léger, JM | 1 |
| Herrmann, C | 1 |
| Malauzat, D | 1 |
| Danot, G | 1 |
| Lombertie, ER | 1 |
| Roehrs, T | 1 |
| Zorick, FJ | 1 |
| Sicklesteel, JM | 1 |
| Wittig, RM | 1 |
| Hartse, KM | 1 |
| Roth, T | 1 |
| Schifano, F | 2 |
| Curran, HV | 2 |
| Wagemans, J | 1 |
| Notebaert, W | 1 |
| Boucart, M | 1 |
| Sperling, R | 1 |
| Greve, D | 1 |
| Dale, A | 1 |
| Killiany, R | 1 |
| Holmes, J | 1 |
| Rosas, HD | 1 |
| Cocchiarella, A | 1 |
| Firth, P | 1 |
| Rosen, B | 1 |
| Lake, S | 1 |
| Lange, N | 1 |
| Routledge, C | 1 |
| Albert, M | 1 |
| Lader, M | 1 |
| Lucki, I | 1 |
| Rickels, K | 1 |
| Geller, AM | 1 |
| Kales, A | 1 |
| Bixler, EO | 1 |
| Soldatos, CR | 1 |
| Jacoby, JA | 1 |
| Kales, JD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Impact of Lorazepam on Cognition in APOE e4 Carriers[NCT00586430] | 36 participants (Actual) | Interventional | 2005-12-31 | Completed | |||
| Bridging Cognitive Aging in Rodents to Man Using fMRI in Amnestic MCI[NCT01044758] | Phase 2 | 96 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Evolution of Memory-related fMRI Activation Over the Course of MCI and AD[NCT00902499] | 160 participants (Anticipated) | Observational | 2006-05-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mnemonic similarity task which assesses long term memory function. Scale ranges from 0-100 with higher scores indicating better memory performance. (NCT01044758)
Timeframe: 2 weeks
| Intervention | percent correct recalled (Mean) |
|---|---|
| aMCI_62.5 | 38 |
| aMCI_62.5 Placebo | 33 |
| aMCI_125 | 33 |
| aMCI_125 Placebo | 28 |
| aMCI_250 | 34 |
| aMCI_250 Placebo | 31 |
| Age Matched Control | 44 |
Measurement of average brain activity in the dentate gyrus / CA3 subregion of the hippocampus measured with BOLD functional MRI in patients with mild cognitive impairment on placebo and on drug compared to average brain activity in this brain area in control subjects. (NCT01044758)
Timeframe: 2 weeks
| Intervention | mean beta coefficient (Mean) |
|---|---|
| aMCI_62.5 | -0.1203 |
| aMCI_62.5 Placebo | 0.4353 |
| aMCI_125 | -0.2238 |
| aMCI_125 Placebo | 0.8814 |
| aMCI_250 | 0.3928 |
| aMCI_250 Placebo | 0.4825 |
| Age Matched Control | -.02507 |
1 review available for lorazepam and Age-Related Memory Disorders
| Article | Year |
|---|---|
Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs.
Topics: Apomorphine; Cognition Disorders; Dopamine Agonists; Excitatory Amino Acid Antagonists; GABA Modulat | 2007 |
5 trials available for lorazepam and Age-Related Memory Disorders
| Article | Year |
|---|---|
The role of sedation tests in identifying sedative drug effects in healthy volunteers and their power to dissociate sedative-related impairments from memory dysfunctions.
Topics: Adult; Affect; Antipsychotic Agents; Arousal; Benzodiazepines; Choice Behavior; Cross-Over Studies; | 2007 |
Effects of hypnotics on memory.
Topics: Adult; Flurazepam; Humans; Hypnotics and Sedatives; Lorazepam; Male; Memory Disorders; Secobarbital; | 1983 |
Pharmacological models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on word valence ratings, priming and recall.
Topics: Adult; Affect; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Lorazepam; Male; Memory | 1994 |
Lorazepam but not diazepam impairs identification of pictures on the basis of specific contour fragments.
Topics: Adult; Diazepam; Double-Blind Method; Female; Humans; Lorazepam; Male; Memory; Memory Disorders; Psy | 1998 |
Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood.
Topics: Adult; Affect; Anxiety; Double-Blind Method; Female; Flicker Fusion; Humans; Hypnotics and Sedatives | 1991 |
8 other studies available for lorazepam and Age-Related Memory Disorders
| Article | Year |
|---|---|
Adverse performance effects of acute lorazepam administration in elderly long-term users: pharmacokinetic and clinical predictors.
Topics: Aged; Aged, 80 and over; Anti-Anxiety Agents; Anxiety; Cross-Over Studies; Double-Blind Method; Emot | 2015 |
Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers.
Topics: Aged; Alleles; Alzheimer Disease; Apolipoprotein E4; Cognition; Cognition Disorders; Cross-Over Stud | 2009 |
Apolipoprotein E epsilon4 allele and lorazepam effects on memory in high-functioning older adults.
Topics: Aged; Aging; Alleles; Apolipoprotein E4; Apolipoproteins E; Dose-Response Relationship, Drug; Geneti | 2005 |
Altered benzodiazepine receptor sensitivity in alcoholism: a study with fMRI and acute lorazepam challenge.
Topics: Adult; Alcoholism; Cerebellum; Chlormethiazole; Cognition Disorders; Drug Administration Schedule; G | 2007 |
[Anxiolytics and mnemonic ability of the aged subject. Apropos of a double-blind study between tiapride and lorazepam].
Topics: Aged; Aging; Arousal; Attention; Benzamides; Double-Blind Method; Humans; Lorazepam; Memory; Memory | 1984 |
Functional MRI detection of pharmacologically induced memory impairment.
Topics: Adult; Anti-Anxiety Agents; Brain; Cross-Over Studies; Double-Blind Method; Humans; Image Processing | 2002 |
Functional MRI detection of pharmacologically induced memory impairment.
Topics: Adult; Anti-Anxiety Agents; Brain; Cross-Over Studies; Double-Blind Method; Humans; Image Processing | 2002 |
Functional MRI detection of pharmacologically induced memory impairment.
Topics: Adult; Anti-Anxiety Agents; Brain; Cross-Over Studies; Double-Blind Method; Humans; Image Processing | 2002 |
Functional MRI detection of pharmacologically induced memory impairment.
Topics: Adult; Anti-Anxiety Agents; Brain; Cross-Over Studies; Double-Blind Method; Humans; Image Processing | 2002 |
Chronic use of benzodiazepines and psychomotor and cognitive test performance.
Topics: Adult; Affect; Aged; Alprazolam; Anti-Anxiety Agents; Benzodiazepines; Clorazepate Dipotassium; Cogn | 1986 |
Lorazepam: effects on sleep and withdrawal phenomena.
Topics: Adult; Humans; Lorazepam; Memory Disorders; Middle Aged; Sleep; Sleep Initiation and Maintenance Dis | 1986 |